Ten years of highly active antiretroviral therapy for HIV infection

被引:67
作者
Chen, Luke F.
Hoy, Jennifer
Lewin, Sharon R. [1 ]
机构
[1] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia
[2] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia
[3] Alfred Hosp, Clin Res Unit, Melbourne, Vic, Australia
关键词
D O I
10.5694/j.1326-5377.2007.tb00839.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past 10 years, the management of HIV infection has been transformed by an increased number of effective antiretrovirals (ARVs), with more convenient dosing and improved tolerability. Optimal management of HIV infection includes at least three effective ARVs; from at least two different drug classes. Current strategies and drugs can effectively control HIV and significantly reduce morbidity and mortality. However, no cure is yet possible. Appropriate use of ARVs leads to suppression of virological replication (to below the limit of detection using commercial assays to measure HIV in plasma) and an increase in CD4(+) T cells with few adverse effects. Greater than 95% adherence to drug therapy is required for effective viral suppression and immunological improvement. Monotherapy, two-drug combinations, sequential ARVs, drug "cycling", and treatment interruptions are ineffective management strategies and lead to earlier disease progression and emergence of drug resistance. Drug-drug interactions are common and caution is required when prescribing ARVs that inhibit or induce the cytochrome P450 pathway.
引用
收藏
页码:146 / 151
页数:6
相关论文
共 58 条
  • [1] [Anonymous], 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002037
  • [2] [Anonymous], 1999, A guide to the development, implementation and evaluation of clinical practice guidelines
  • [3] Paradoxes of adherence and drug resistance to HIV antiretroviral therapy
    Bangsberg, DR
    Moss, AR
    Deeks, SG
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) : 696 - 699
  • [4] Tenofovir-related nephrotoxicity in HIV-infected patients
    Barrios, A
    García-Benayas, T
    González-Lahoz, J
    Soriano, V
    [J]. AIDS, 2004, 18 (06) : 960 - 963
  • [5] Beck EJ, 2004, AIDS, V18, P2411
  • [6] A case-control study of HIV seroconversion in health care workers after percutaneous exposure
    Cardo, DM
    Culver, DH
    Ciesielski, CA
    Srivastava, PU
    Marcus, R
    Abiteboul, D
    Heptonstall, J
    Ippolito, G
    Lot, F
    McKibben, P
    Bell, DM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (21) : 1485 - 1490
  • [7] Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - A randomized trial
    Carr, A
    Workman, C
    Smith, DE
    Hoy, J
    Hudson, J
    Doong, N
    Martin, A
    Amin, J
    Freund, J
    Law, M
    Cooper, DA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02): : 207 - 215
  • [8] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
    Carr, A
    Samaras, K
    Burton, S
    Law, M
    Freund, J
    Chisholm, DJ
    Cooper, DA
    [J]. AIDS, 1998, 12 (07) : F51 - F58
  • [9] HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study
    Carr, A
    Hudson, J
    Chuah, J
    Mallal, S
    Law, M
    Hoy, J
    Doong, N
    French, M
    Smith, D
    Cooper, DA
    [J]. AIDS, 2001, 15 (14) : 1811 - 1822
  • [10] Health-related quality of life after 1 year of highly active antiretroviral therapy
    Carrieri, P
    Spire, B
    Duran, S
    Katlama, C
    Peyramond, D
    François, C
    Chêne, G
    Lang, JM
    Moatti, JP
    Leport, C
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (01) : 38 - 47